Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation.
A four-yr-old boy developed a solitary metastasis nine months after living-related liver transplantation for unresectable hepatoblastoma. After resection of the metastatic lesion, he received an auto-PBSCT with a double-conditioning regimen consisting of melphalan and thiotepa. Auto-PBSCT could be safely performed without any serious regimen-related toxicity or infection. However, transient cessation of tacrolimus during myelosuppression resulted in graft rejection of the liver just after hematological engraftment, but rejection was resolved by tacrolimus and methylprednisolone. The patient is alive and free from disease two yr after auto-PBSCT without any signs of graft rejection. High-dose chemotherapy using this conditioning regimen may be feasible for recurrent hepatoblastoma after liver transplantation in terms of safety and anti-tumor activity.
Niwa
Akira
A
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Umeda
Katsutsugu
K
Awaya
Tomonari
T
Yui
Yoshihiro
Y
Matsubara
Hiroshi
H
Hiramatsu
Hidefumi
H
Watanabe
Ken-Ichiro
K
Adachi
Souichi
S
Itoh
Takashi
T
Uemoto
Shinji
S
Nakahata
Tatsutoshi
T
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002675:Child, Preschool; D006084:Graft Rejection; D018197:Hepatoblastoma / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011379:Prognosis; D012008:Recurrence; D016559:Tacrolimus / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016559:Tacrolimus